Etcembly Announces Breakthrough in Optimising TCR Assets
Etcembly Announces Breakthrough in Optimising TCR Assets Successful Financing Brings in Singapore VC iGlobe Partners  Oxfordshire, UK, 14 December 2022 – Etcembly, a tech-bio company transforming the precision, scale, and speed of development of T cell receptor (TCR) immunotherapies, today annou...
United Kingdom Michelle Teng Jacob Hurst Etcembly Announces Breakthrough Financing Brings Globe Partners
Source: pharmiweb.com